乌司他丁联合生长抑素治疗重症急性胰腺炎的临床效果分析

Analysis of the Clinical Effect of Ulinastatin Combined with Somatostatin in the Treatment of Severe Acute Pancreatitis

目的分析乌司他丁联合生长抑素治疗重症急性胰腺炎的临床效果。方法病例纳入时间段为2010年6月至2018年5月,纳入范围为我院住院部收治重症急性胰腺炎患者,共纳入70例。按照数字随机表方法进行分组处理,组别设置为对照组/实验组,各组平均分配患者35例。对照组患者采取单用生长抑素治疗方案,实验组患者采取乌司他丁联合生长抑素治疗方案。对比观察两组患者在临床疗效;干预前/后白蛋白、白细胞计数、血淀粉酶水平;并发症发生率方面的差异。结果实验组患者临床干预总有效率为94.29%(33/35),显著高于对照组,经检验有统计学差异(P<0.05)。临床干预前,两组患者白蛋白、白细胞计数、血淀粉酶水平对比,经检验无统计学差异(P>0.05);临床干预后,实验组患者白蛋白均值(30±0.2)g/L,显著高于对照组;白细胞计数均值(11.0±1.1)×10^(9)/L,血淀粉酶均值(415.8±35.6)U/L,显著低于对照组;经检验有统计学差异(P<0.05)。治疗期间实验组患者并发症发生率为11.43%(4/35),显著低于对照组,经检验有统计学差异(P<0.05)。实验组患者平均住院时间为(21.5±1.6)d,病死率为5.71%(2/35),均明显低于对照组,经检验有统计学差异(P<0.05)。结论乌司他丁联合生长抑素治疗重症急性胰腺炎的临床效果确切,其总有效率优于单纯生长抑素方案,且对改善患者白蛋白、白细胞以及血淀粉酶水平,降低并发症发生率有积极作用,值得推广。

Objective To analyze the clinical effect of ulinastatin combined with somatostatin statins in treating of severe acute pancreatitis.Methods Cases in time for June 2010 to May 2018,included in the scope of the inpatient admitted to our hospital patients with severe acute pancreatitis,included in the total of 70 cases.According to the number of random grouping processing table method,group/group is set to the control group,each group of 35 patients is evenly distributed.In the control group,somatostatin therapy plan in patients with experimental group patients treated with ulinastatin combined somatostatin.Compared two groups of patients in the clinical curative effect;Intervention before/after albumin,white blood cell count,blood amylase levels;Differences in the incidence of complications.Results The total effective rate was 94.29%(33/35)in the experimental group,which was significantly higher than that in the control group(P<0.05).Before the clinical intervention,two groups of patients with albumin,white blood cell count,serum amylase level,compared with no significant difference(P>0.05);clinical intervention,the experimental group of patients with albumin(30±0.2)g/L,significantly higher than the control group(11+1.1)10^(9)/L,blood amylase(415.8+35.6)U/L,significantly lower than the control group(P<0.05).The complication rate of the experimental group was 11.43%(4/35),which was significantly lower than that of the control group(P<0.05).Experimental group patients average hospitalization time was(21.5+1.6)d,the case fatality rate was 5.71(2/35),were significantly lower than the control group,the test was statistically different(P<0.05).Conclusion The ulinastatin combined with the growth effect of somatostatin in the treatment of severe acute pancreatitis(SAP).The clinical inpact of exact,the total efficiency is better than the simple somatostatin scheme,and to improve patient albumin,white blood cells and serum amylase level,reduce complication rate has a positive effect and is worthy of being popularized.